CSIMarket
 


Moleculin Biotech Inc   (MBRX)
Other Ticker:  
 

Moleculin Biotech Inc 's Tangible Leverage Ratio

MBRX's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to net new borrowings of 176.94%, Tangible Leverage Ratio fell to 0.81, below the Moleculin Biotech Inc 's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 112 other companies have achieved lower Tangible Leverage Ratio than Moleculin Biotech Inc in the IV Quarter 2023. While Tangible Leverage Ratio total ranking has deteriorated compared to the third quarter 2023 from 402 to 762 .

Explain Tangible Leverage Ratio?
What is MBRX Market Share?
What are MBRX´s Total Liabilities?


MBRX Tangible Leverage Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Tangible Equity Change -63.64 % -49.25 % -47.26 % -43.86 % -39.5 %
Y / Y Total Liabilities Change 132.15 % -36.95 % -0.71 % -12.35 % 2.63 %
Tangible Leverage Ratio MRQ 0.81 0.18 0.24 0.16 0.13
MBRX's Total Ranking # 762 # 402 # 579 # 407 # 348
Seq. Tangible Equity Change -37.79 % -17.62 % -15.68 % -15.85 % -13.17 %
Seq. Total Liabilities Change 176.94 % -35.96 % 27.31 % 2.81 % -24.79 %



Tangible Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 113
Healthcare Sector # 226
Overall Market # 761


Tangible Leverage Ratio Statistics
High Average Low
3.82 0.9 0.08
(Sep 30 2020)   (Dec 31 2021)




Financial Statements
Moleculin Biotech Inc 's Tangible Equity $ 15 Millions Visit MBRX's Balance sheet
Moleculin Biotech Inc 's Total Liabilities $ 12 Millions Visit MBRX's Balance sheet
Source of MBRX's Sales Visit MBRX's Sales by Geography


Cumulative Moleculin Biotech Inc 's Tangible Leverage Ratio

MBRX's Tangible Leverage Ratio for the trailling 12 Months

MBRX Tangible Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Tangible Equity TTM Growth -63.64 % -49.25 % -47.26 % -43.86 % -39.5 %
Y / Y Total Liabilities TTM Growth 132.15 % -36.95 % -0.71 % -12.35 % 2.63 %
Tangible Leverage Ratio TTM 0.28 0.17 0.16 0.14 0.12
Total Ranking TTM # 505 # 215 # 2 # 220 # 2
Seq. Tangible Equity TTM Growth -37.79 % -17.62 % -15.68 % -15.85 % -13.17 %
Seq. Total Liabilities TTM Growth 176.94 % -35.96 % 27.31 % 2.81 % -24.79 %


On the trailing twelve months basis Due to the net new borrowings of 176.94% during the trailing twelve months finishing in the IV Quarter 2023, cumulativeTangible Leverage Ratio improved to 0.28, below the Moleculin Biotech Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 112, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Moleculin Biotech Inc . While Tangible Leverage Ratio total ranking has deteriorated during the twelve months ending in the IV Quarter 2023, compared to the prior period, from 215 to 505.

Explain Tangible Leverage Ratio?
What is MBRX Market Share?
What are MBRX´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 113
Healthcare Sector # 226
Within the Market # 505


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
3.82 0.9 0.08
(Sep 30 2020)   (Dec 31 2021)




Companies with similar Tangible Leverage Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Tangible Equity
Biovie Inc   2.11 $ 13.981  Millions$ 6.623  Millions
Liquidia Corporation  1.78 $ 71.039  Millions$ 39.960  Millions
Summit Therapeutics Inc   1.65 $ 125.257  Millions$ 75.799  Millions
Xoma Corporation  1.64 $ 145.580  Millions$ 88.721  Millions
Ocular Therapeutix Inc   1.54 $ 139.916  Millions$ 91.131  Millions
Theriva Biologics inc   1.52 $ 17.528  Millions$ 11.508  Millions
Eton Pharmaceuticals Inc   1.51 $ 16.263  Millions$ 10.738  Millions
Lifevantage Corp  1.31 $ 35.375  Millions$ 26.918  Millions
2seventy Bio Inc   1.25 $ 310.126  Millions$ 248.706  Millions
Verastem inc   1.24 $ 71.185  Millions$ 57.374  Millions
23andme Holding Co  1.22 $ 231.023  Millions$ 189.010  Millions
Cara Therapeutics inc   1.20 $ 68.759  Millions$ 57.085  Millions
Talphera Inc   1.19 $ 6.290  Millions$ 5.286  Millions
Sonoma Pharmaceuticals Inc   1.18 $ 7.926  Millions$ 6.692  Millions
Sonnet Biotherapeutics Holdings Inc   1.07 $ 2.765  Millions$ 2.572  Millions
Arvinas Inc   0.98 $ 644.600  Millions$ 660.000  Millions
Royalty Pharma Plc  0.97 $ 9,772.199  Millions$ 10,084.289  Millions
Macrogenics Inc   0.96 $ 145.805  Millions$ 152.613  Millions
Entrada Therapeutics Inc   0.94 $ 226.832  Millions$ 242.360  Millions
Spyre Therapeutics Inc   0.86 $ 157.843  Millions$ 184.016  Millions
Immunic Inc   0.85 $ 24.729  Millions$ 28.931  Millions
Generation Bio Co   0.84 $ 171.630  Millions$ 203.128  Millions
Azitra Inc   0.81 $ 2.202  Millions$ 2.702  Millions
Moleculin Biotech Inc   0.81 $ 12.144  Millions$ 14.925  Millions
Ardelyx Inc   0.78 $ 130.763  Millions$ 166.816  Millions
Nurix Therapeutics Inc   0.77 $ 155.105  Millions$ 200.493  Millions
Harmony Biosciences Holdings inc   0.74 $ 244.962  Millions$ 329.884  Millions
Hutchmed china Limited  0.74 $ 549.232  Millions$ 743.387  Millions
Elite Pharmaceuticals Inc   0.71 $ 28.283  Millions$ 40.072  Millions
Paxmedica Inc   0.68 $ 2.295  Millions$ 3.385  Millions

Date modified: 2024-03-23T15:13:04+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com